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(MPC), nab-paclitaxel plus gemcitabine (nab-P/Gem) demonstrated greater efficacy but higher
rates of peripheral neuropathy (PN) versus Gem. This exploratory analysis aimed to charac-
terise the frequency, duration, and severity of PN with nab-P/Gem in the MPACT study.
Patients and methods: Patients with previously untreated MPC received nab-P/Gem or Gem.
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D. Goldstein et al. / European Journal of Cancer 52 (2016) 85e9186Regulatory Activities Queries (SMQ) and graded by National Cancer Institute Common Ter-
minology Criteria for Adverse Events (NCI CTCAE) version 3.0. A case report form was
completed by physicians on day 1 of each cycle (also graded by NCI CTCAE version 3.0).
Results: In the nab-P/Gem arm, 227/421 patients (54%) experienced any-grade PN and 70
(17%) experienced grade III PN. No grade IV PN was reported. Most early-onset PN events
were grade I, and treatment-related grade III PN occurred in 7% of patients who received up
to three cycles of nab-P. Of those who developed grade III PN with nab-P/Gem treatment, 30
(43%) improved to grade I (median time to improvementZ 29 days) and 31 (44%) resumed
therapy. Development of PN was associated with efficacy; median overall survival in patients
with grade III versus 0 PN was 14.9 versus 5.9 months (hazard ratio, 0.33; P < .0001).
Conclusions: nab-P/Gem was associated with grade III PN in a small percentage of patients.
PN development was associated with longer treatment duration and improved survival. Grade
III PN was reversible to grade I in many patients (median z 1 month) NCT00844649.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Advanced pancreatic cancer (PC) is associated with
poor survival, with a 5-year survival rate ofz2% in the
United States [1]. Until recently, patients with advanced
PC had limited treatment options. nab-Paclitaxel plus
gemcitabine (nab-P/Gem) is a new treatment option that
was approved based on the results of the phase III
MPACT trial, in which nab-P/Gem demonstrated su-
periority over Gem [2]. The median overall survival (OS)
for nab-P/Gem versus Gem was 8.5 versus 6.7 months
(hazard ratio [HR], 0.72; P < .001), the median
progression-free survival (PFS) was 5.5 versus 3.7
months (HR, 0.69; P < .001), and the overall response
rate (ORR) by independent review was 23% versus 7%
(P < .001). In an updated report, the final OS for nab-P/
Gem versus Gem was 8.7 versus 6.6 months (HR, 0.72;
P < .001) [3].
Peripheral neuropathy (PN) can be dose limiting and
can persist indefinitely in some cases [4e6]. However,
proper management of PN can potentially extend
treatment. nab-P was developed to overcome the
formulation limitations attributed to the solvent Kolli-
phor EL (formerly called Cremophor EL) and improve
the safety profile and therapeutic index of solvent-based
paclitaxel (sb-P) [7]. In phase II/III trials of various
tumour types, nab-P regimens demonstrated improved
efficacy and tolerability compared with solvent-based
taxanes [8e10]. Compared with sb-P/carboplatin (C),
nab-P/C was associated with significantly lower rates of
grade III PN in a phase III trial of patients with
advanced non-small cell lung cancer (NSCLC) [10].
MPACT was the largest trial to date to evaluate a
taxane combination in a large population of patients
with advanced PC [2]. As expected, the combination arm
was associated with a higher incidence of grade III/IV
adverse events (AEs), including PN. Understanding and
managing PN is an integral part of providing optimal
therapy for patients with cancer; thus, the frequency,duration, and severity of PN associated with nab-P/Gem
therapy were investigated in this exploratory analysis of
the MPACT trial.
2. Patients and methods
This subgroup analysis of the phase IIIMPACT trial was
not pre-specified in the study protocol. The study design
and patient characteristics have been described previ-
ously [2]; key parameters are described below. The inde-
pendent ethics committee at each participating institution
approved the study. All patients provided written
informed consent before the initiation of the study.
2.1. Patients
This study enrolled adult patients with a Karnofsky
performance status (KPS) 70 and histologically or
cytologically confirmed metastatic adenocarcinoma of
the pancreas. Patients were required to have adequate
hepatic, haematologic, and renal function (including
bilirubin level  the upper limit of normal, absolute
neutrophil count 1.5  109/L, and haemoglobin level
9 g/dl) and baseline PN grade I.
2.2. Study design and treatment
Patients were randomised (1:1) to receive a 30e40-
minute intravenous infusion of nab-P 125 mg/m2, fol-
lowed by Gem 1000 mg/m2 on days 1, 8, 15, 29, 36, and
43, or Gem alone 1000 mg/m2 weekly for 7 of 8 weeks
(cycle 1). In subsequent cycles, patients received treat-
ment on days 1, 8, and 15 every 4 weeks until disease
progression or unacceptable toxicity.
2.3. Safety assessments
Investigators monitored treatment-related AEs and
serious AEs; weekly central laboratory data; and rates
Table 1
Peripheral neuropathy (per SMQ) in the treated population.
Peripheral neuropathy events, n (%)a nab-P/Gem
(n Z 421)
Patients with grade I peripheral neuropathy AE 227 (54)
Worst grade of peripheral neuropathy
Grade I 96 (23)
Grade II 61 (15)
Grade III 70 (17)
Patients with 1 SAE of peripheral neuropathy 3 (1)
AE, adverse event; Gem, gemcitabine; MedDRA, Medical Dictionary
for Regulatory Activities; nab-P, nab-paclitaxel; NCI CTCAE, Na-
tional Cancer Institute Common Terminology Criteria for Adverse
Events; SAE, serious adverse event; SMQ, Standardised MedDRA
Queries.
a Based on MedDRA SMQ (broad range) graded by NCI CTCAE.
D. Goldstein et al. / European Journal of Cancer 52 (2016) 85e91 87of dose reductions, dose interruptions, and premature
discontinuations. Patients who received 1 dose of
study drug (treated population) were evaluated by
physicians for safety using the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events
(NCI CTCAE), version 3.0 [11], and AEs were coded to
correspond with the preferred terms in the Medical
Dictionary for Regulatory Activities (MedDRA),
version 15.0. PN was graded according to NCI CTCAE
(Table A.1). PN was coded using Standardised Med-
DRA Queries (SMQ; broad scope); preferred terms
included neuropathy peripheral, peripheral sensory
neuropathy, peripheral motor neuropathy, and other
less commonly observed PN AEs. SMQ were not
generated for treatment-emergent PN that resulted in
dose reduction. PN was also evaluated by physicians
using case report forms.
2.4. Statistical methods
For incidence of PN by cycle, if a patient had multiple
events of PN during a cycle, the worst grade among
those events was counted. If a patient had PN events in
>1 cycle, the patient was counted in each of the corre-
sponding cycles by worst grade reported in the respec-
tive cycle. Because patients discontinued from the study
over time, the number of patients who received 1 dose
of treatment in a specific treatment cycle was used as the
denominator in the calculation of the percentage of
patients with PN for that cycle. For total incidence of
PN by grade, each patient was represented by the worst
grade reported over the entire treatment period; in other
words, each patient was counted only once even if the
patient reported >1 event in multiple cycles. The asso-
ciation of any grade of PN (none, I, II, or III) and OS
was analysed with a Cox regression model by treating
grade of PN as a continuous variable. A Cox regression
model including PN (grade III versus grades none/I) as a
time-varying covariate and other prognostic factors was
used to determine the association of OS and high-grade
PN.
2.5. Dose modifications due to PN
Per protocol, nab-P treatment was withheld in pa-
tients who experienced grade III PN, while Gem
treatment could be continued. Once grade III PN
improved to grade I, nab-P treatment could be
resumed at a lower dose level in subsequent treatment
cycles.
3. Results
3.1. Patients
Overall, 431 patients were randomised to the nab-P/
Gem arm, with 421 evaluable for safety. By SMQevaluation, rates of all-grade and grade III PN for nab-
P/Gem were 54% and 17%, respectively (Table 1).
Approximately 1% of patients had 1 serious AE of PN
with nab-P/Gem. No grade IV PN was observed. Rates
of grade III physician-assessed PN (Table A.2) were
similar to those per the SMQ evaluation. In the sub-
group of patients who received nab-P/Gem and devel-
oped grade III PN (n Z 70, assessed by MedDRA),
most baseline characteristics were similar to those of the
intent-to-treat (ITT) population [2] as well as those in
patients not developing PN (no grade). A few excep-
tions should be noted between patients who developed
grade III PN and those who did not develop PN. A
higher proportion of patients with grade III PN versus
those without PN were from North America (66%
versus 53%) and had a KPS of 90e100 at baseline (66%
versus 51%). Furthermore, although median baseline
carbohydrate antigen 19-9 was lower in patients who
developed grade III PN (1583 U/ml) than in those who
did not (2820 U/ml), we noted that the median number
of metastatic sites, a measure of tumour burden, was
similar between the groups (two each). No excess of
comorbidities was observed within these subgroups
versus the ITT population [2], including diabetes and
renal impairment.
3.2. Development of PN
Most PN events associated with nab-P/Gem treatment
occurred within the first three cycles and were grade I.
Most grade III PN developed after cycle 3; the rate of
grade III PN doubled after cycle 4 and peaked at cycle 7
(Fig. 1). Seventy patients developed grade III PN during
treatment. The rate of grade III PN ranged from 2e4%
within each of the first three cycles; the cumulative
incidence of grade III PN in patients treated for <3
cycles was 7%. The median time to improvement from
grade III PN to grade I was 29 d. Of the 30 patients
(43%) who improved to grade I, 23 (77%) did so within
28 d (Table 2).
Fig. 1. Incidence of treatment-emergent peripheral neuropathy (per Standardised Medical Dictionary for Regulatory Activities Queries) in
the nab-paclitaxel/gemcitabine arm by cycle and grade. The data represent the worst grade of an adverse event experienced by a patient,
and a patient may have been counted in >1 cycle.
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Patients with higher grades of PN generally had greater
treatment exposure. Patients in the nab-P/Gem arm who
developed grade III PN received a median of six cycles,
while those who developed grades none to II PN
received a median of three cycles (Table 3). Patients
receiving nab-P/Gem who developed grade 3 PN had a
longer median duration of treatment than those with
grades none to II PN (195 versus 113 d). A higher me-
dian number of nab-P doses were administered in pa-
tients who developed grade III PN versus those who
developed grades none to II PN (18 versus 11). Patients
with grade III PN had a higher median cumulative dose
of nab-P than those with grade none to II PN
(1987.5 mg/m2 versus 1275.0 mg/m2); average nab-P
dose intensity was similar between these two cohorts
(data not shown).
3.4. Dose modifications due to PN in patients receiving
nab-P/Gem
Per protocol, most patients developing grade III PN had
1 nab-P dose modification (dose delay [80%] and/orTable 2
Improvement in grade III peripheral neuropathy over time in the nab-
P/Gem arm.
Grade III peripheral neuropathy nab-P/Gem (n Z 70)
Improvement to grade I
Patients, n (%) 30 (43)
Time to improvement
 14 d 9 (30)
>14 to 28 d 14 (46.7)
>28 to 42 d 5 (16.7)
>42 d 2 (6.6)
Gem, gemcitabine; nab-P, nab-paclitaxel.reduction [41%]), most of which occurred at or before
cycle 6 (Table 4). Most patients required only one dose
modification. Of the 31 patients who developed grade
III PN and were able to resume treatment after a dose
delay, 21 (68%) received a total of 6 cycles of therapy,
and only 4 (13%) discontinued treatment due to PN. Of
the 70 patients who developed grade III PN, 40 did not
improve to grade I; most of these patients received no
further treatment with nab-P.
3.5. Efficacy outcomes in patients who developed PN after
treatment with nab-P/Gem
Patients who developed PN (grades IeIII) had signifi-
cantly better outcomes versus those who did not (Table
3). Among patients with grade III PN versus no PN, the
ORR was 43% versus 8% (relative risk reduction, 5.54;
95% confidence interval [CI], 3.18e9.67; P < .0001), the
median PFS was 9.1 versus 3.5 months (HR, 0.27; 95%
CI, 0.18e0.41; P < .0001), and the median OS was 14.9
versus 5.9 months (HR, 0.33; 95% CI, 0.23e0.48;
P < .0001). Each increasing grade of PN was associated
with a longer median OS than the grade before it
(Fig. 2). The 1-year OS rate for patients who developed
grade III PN versus no PN was 61% versus 17%, and the
2-year OS was 24% versus 3%. Even in patients who had
>4 cycles of therapy, those who developed grade III PN
versus no PN had an improved survival (median OS,
15.7 versus 11.4 months; Table A.3); these patients
received a similar median number of nab-P doses (Table
A.4).
The development of PN during treatment with nab-P/
Gem (from grades none to III) was associated with
longer survival; every grade increase was associated with
a 35% reduction in risk of death (HR, 0.65; 95% CI,
0.58e0.72; P < .0001). In multivariate analysis, after
Table 3
Efficacy outcomes in patients by grade of peripheral neuropathy developed in the nab-paclitaxel/gemcitabine arm.
Outcome Grade of peripheral neuropathy developed No grade versus III
0 (n Z 194) 1 (n Z 96) 2 (n Z 61) 3 (n Z 70) HR/RRR P for HR/RRR
OS, median (95% CI), months 5.9 (4.67e6.90) 9.0 (8.34e12.32) 12.6 (9.59e15.74) 14.9 (11.86e19.15) 0.33 (0.23e0.48) <.0001
PFS, median (95% CI), months 3.5 (3.06e3.78) 5.6 (4.47e6.18) 9.3 (7.23e12.62) 9.1 (7.52e11.50) 0.27 (0.18e0.41) <.0001
ORR (95% CI), % 8 (4.4e12.4) 29 (20.3e39.3) 43 (30.0e55.9) 43 (31.1e55.3) 5.54 (3.18e9.67) <.0001
Number of cycles administered,
median (min, max)
1 (1, 13) 4 (1, 17) 6 (1, 23) 6 (1, 22) e e
CI, confidence interval; HR, hazard ratio; max, maximum; min, minimum; ORR, overall response rate; OS, overall survival; PFS, progression-free
survival; RRR, relative risk reduction.
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vious reports (baseline KPS, presence of liver metasta-
ses, age, and region) [12], PN (grade III versus grades
none/I) as a time-varying covariate remained associated
with survival for all patients (HR, 0.55; 95% CI,
0.39e0.79; P Z .0007; Table A.5).
4. Discussion
This exploratory analysis of the MPACT trial revealed
that, although the incidence of all-grade PN was rela-
tively high in patients receiving nab-P/Gem, no grade IV
PN was reported, with most events being grades II.Table 4
nab-P dose modifications due to grade III peripheral neuropathy and
retreatment.
Patients with  1 nab-P dose modification
due to grade III peripheral neuropathya
nab-P/Gem (n Z 70)
Total dose delays, n (%)
Cycle 1 6 (8.6)
Cycle 2 9 (12.9)
Cycle 3 7 (10.0)
Cycle 4 12 (17.1)
Cycle 5 13 (18.6)
Cycle 6 8 (11.4)
>6 cycles 13 (18.6)
Total dose reductions, n (%)
Cycle 1 4 (5.7)
Cycle 2 9 (12.9)
Cycle 3 4 (5.7)
Cycle 4 4 (5.7)
Cycle 5 6 (8.6)
Cycle 6 2 (2.9)
>6 cycles 5 (7.1)
Patients retreated after developing grade III
peripheral neuropathy, n (%)
31 (44.2)
Number of cycles administered, n (%)
1 2 (6.5)
2 1 (3.2)
3 3 (9.7)
4 3 (9.7)
5 1 (3.2)
6 5 (16.1)
>6 16 (51.6)
Gem, gemcitabine; nab-P, nab-paclitaxel.
a Patients were counted multiple times if they had dose modifications
in different cycles.This is consistent with previous studies of weekly nab-P
regimens in advanced PC and advanced NSCLC
[10,13,14]. Despite the development of grade III PN with
nab-P/Gem, PN was manageable with dose reductions
or delays in nearly half of those affected, considering
most patients who resumed treatment received 6 cycles
of therapy total and the duration of treatment in pa-
tients developing grade III PN was 6.4 months. Of pa-
tients resuming treatment, only 13% discontinued nab-P
therapy due to PN; thus, resumption of therapy
appeared to be safe in these patients.
The course of grade III PN related to nab-P therapy
in this study was cumulative in nature. The median time
to onset of grade III PN was 140 d [2], and grade III PN
peaked at cycle 7. This is important to note because
patients who experienced grade III PN received a me-
dian of six cycles of nab-P/Gem; the median number of
cycles delivered in this arm was three in the ITT popu-
lation and three in those not developing PN [15].
Therefore, development of grade III PN did not impact
administration of nab-P/Gem.
Patients receiving nab-P/Gem and developing PN had
a significantly better ORR, median OS, and median PFS
than patients not developing PN. Interestingly, the ef-
ficacy outcomes in patients developing grade III PN
were numerically better than those observed in the ITT
population (no formal statistical analyses were per-
formed) [2]. Baseline characteristics in patients devel-
oping PN were similar to those in the ITT population
and in patients who did not develop PN [2]. Therefore,
differences in patient characteristics likely did not play a
role in the differences observed in efficacy outcomes in
these patient subsets. PN maintained an association with
survival after multivariable analysis of other known
prognostic factors. The most likely explanation is a
biologic one related to chemoresponsiveness: patients
with tumours that are intrinsically chemoresponsive
have resultant higher response rates and, thus, an
increased chance of prolonged treatment and ultimately
of developing grade III PN. However, even in those with
longer treatment duration, patients developing PN
gained a survival advantage. Ongoing study of bio-
markers may reveal novel insights into predictive factors
for prolonged benefit. Single nucleotide polymorphisms
Fig. 2. Kaplan-Meier curve for overall survival by grade of peripheral neuropathy in the nab-paclitaxel/gemcitabine arm.
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related neuropathy, and these may be the subject of
future work [16].
Fluorouracil, leucovorin, irinotecan, and oxaliplatin
(FOLFIRINOX) have also demonstrated significant
clinical benefit over single-agent Gem [17]. Results
from a recent meta-analysis of randomised phase III
trials in patients with advanced PC (N Z 9989)
demonstrated that FOLFIRINOX was ranked the
worst of six treatments with available data (including
nab-P/Gem) with respect to development of grade III
PN [18]. The neuropathy that results with FOLFIR-
INOX is likely due to oxaliplatin, as neurotoxicity is a
common dose-limiting toxicity of this agent [19,20].
Unlike in our findings with nab-P, PN caused by oxa-
liplatin can persist for many months after discontinu-
ation [21]. In a single-centre study of 24 patients treated
with oxaliplatin, nearly 80% reported residual symp-
toms of PN at a median of 25 months post-therapy [22].
Although 38% of the residual symptoms were classified
as grade I, 29% and 13% were classified as grades II and
III, respectively. More than 40% of patients reported
significant functional issues with daily tasks, like
walking and fine-motor skills. A second study of 20
patients with colorectal cancer previously treated with
oxaliplatin (median of 13 months after therapy) re-
ported similar findings [23]; 60% of patients self-
reported significant physical limitations due to PN.
These findings support the fact that chemotherapy-
related PN can affect patient quality of life during
and after treatment. Therefore, choice of therapy,
particularly in the adjuvant setting, will need to take
into account the competing risk of long-term toxicity,
such as persistent neurotoxicity, and follow appro-
priate management strategies, such as careful moni-
toring for PN development and dose modifications,
when it is identified.In conclusion, this exploratory analysis of the
MPACT trial demonstrated that although nab-P/Gem
was associated with a higher rate of PN than Gem, the
majority of PN experienced was grade II. No patients
developed grade IV PN, and many of those who devel-
oped grade III PN saw improvement to grade I within
z 1 month. These findings were consistent with those of
previous studies of weekly nab-P regimens in patients
with advanced solid tumours [9,10,14].
Conflict of interest statement
DG: consultant or advisory role and research fund-
ing, Celgene Corporation; DDVH: consultant or advi-
sory role, honoraria, and research funding, Celgene
Corporation; MM: consultant or advisory role and
research funding, Celgene Corporation; EG: research
funding, Celgene Corporation; GT: nothing to disclose;
RKR: consultant or advisory role, honoraria, and
research funding, Celgene Corporation; TM: consultant
or advisory role and honoraria, Celgene Corporation;
HL: employment or leadership position and stock
ownership, Celgene Corporation; RP: employment or
leadership position and stock ownership, Celgene Cor-
poration; SF: employment or leadership position and
stock ownership, Celgene Corporation; BL: employ-
ment or leadership position and stock ownership, Cel-
gene Corporation.
Role of the funding source
This study was supported by funding from Celgene
Corporation. Employees of Celgene Corporation were
involved in the study design; the collection, analysis, and
interpretation of data; the writing of the manuscript;
and the decision to submit the manuscript for
publication.
D. Goldstein et al. / European Journal of Cancer 52 (2016) 85e91 91Acknowledgements
The authors thank all participating sites and in-
vestigators for their support with the clinical study, as
well as Peng Wu for his data programming support. The
study was funded by Celgene Corporation. Medical
writing assistance was provided by Christopher Carter,
PhD, of MediTech Media and funded by Celgene Cor-
poration. All authors had full access to the data and are
fully responsible for content and editorial decisions for
this manuscript. David Goldstein had final re-
sponsibility for the decision to submit for publication.
Appendix A. Supplementary data
Supplementary data related to this article can be found
at http://dx.doi.org/10.1016/j.ejca.2015.10.017.
References
[1] Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N,
Altekruse SF, et al. SEER cancer statistics review, 1975e2010.
Bethesda, MD: National Cancer Institute; 2013. http://seer.
cancer.gov/csr/1975_2010.
[2] Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J,
Moore M, et al. Increased survival in pancreatic cancer with nab-
paclitaxel plus gemcitabine. N Engl J Med 2013 Oct 31;369(18):
1691e703.
[3] Goldstein D, El-Maraghi RH, Hammel P, Heinemann V,
Kunzmann V, Sastre J, et al. Nab-paclitaxel plus gemcitabine for
metastatic pancreatic cancer: long-term survival from a phase III
trial. J Natl Cancer Inst 2015 Jan 31;107(2). http:
//dx.doi.org/10.1093/jnci/dju413.
[4] Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE,
Ettinger DS, Grochow LB, et al. Phase I and pharmacologic study
of paclitaxel and cisplatin with granulocyte colony-stimulating
factor: neuromuscular toxicity is dose-limiting. J Clin Oncol
1993 Oct;11(10):2010e20.
[5] Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F.
Diagnosis, management, and evaluation of chemotherapy-
induced peripheral neuropathy. Semin Oncol 2006 Feb;33(1):
15e49.
[6] Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML,
Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity:
a critical analysis. CA Cancer J Clin 2013 NoveDec;63(6):
419e37.
[7] Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased
antitumor activity, intratumor paclitaxel concentrations, and
endothelial cell transport of cremophor-free, albumin-bound
paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
Clin Cancer Res 2006 Feb 15;12(4):1317e24.
[8] Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N,
Bhar P, et al. Phase III trial of nanoparticle albumin-bound
paclitaxel compared with polyethylated castor oil-based pacli-
taxel in women with breast cancer. J Clin Oncol 2005 Nov 1;
23(31):7794e803.
[9] Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN,
Manikhas GM, Clawson A, et al. Significantly longer
progression-free survival with nab-paclitaxel compared withdocetaxel as first-line therapy for metastatic breast cancer. J Clin
Oncol 2009 Aug 1;27(22):3611e9.
[10] Socinski MA, Bondarenko I, Karaseva NA, Makhson AM,
Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in
combination with carboplatin versus solvent-based paclitaxel plus
carboplatin as first-line therapy in patients with advanced non-
esmall-cell lung cancer: final results of a phase III trial. J Clin
Oncol 2012 Jun 10;30(17):2055e62.
[11] National Cancer Institute. Cancer Therapy Evaluation Program.
Common terminology criteria for adverse events v 3.0. 2006.
Available at: http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/docs/ctcaev3.pdf [accessed 13.07.15].
[12] Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V,
Weekes C, et al. Prognostic factors of survival in a randomized
phase III trial (MPACT) of weekly nab-paclitaxel plus gemcita-
bine versus gemcitabine alone in patients with metastatic
pancreatic cancer. Oncologist 2015 Feb;20(2):143e50.
[13] Sakai H, Ko A, Renschler MF, Socinski MA. Nab-paclitaxel in
combination with carboplatin as first-line therapy in patients with
advanced non-small cell lung cancer (NSCLC): analysis of pe-
ripheral neuropathy. In: Poster presented at the 15th World
Conference on Lung Cancer; Sydney, Australia; October 27e30,
2013 [poster P1 10 018].
[14] Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA,
Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an
active regimen in patients with advanced pancreatic cancer: a
phase I/II trial. J Clin Oncol 2011 Dec 1;29(34):4548e54.
[15] Goldstein D, Von Hoff DD, Moore M, Greeno E, Tortora G,
Ramanathan RK, et al. Evaluation of peripheral neuropathy in a
phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus
gemcitabine (gem) vs gem alone for patients with metastatic
adenocarcinoma of the pancreas. In: Abstract presented at the
European Cancer Congress; Amsterdam, The Netherlands;
September 27eOctober 1, 2013 [abstract 2.583].
[16] Park SB, Kwok JB, Loy CT, Friedlander ML, Lin CS,
Krishnan AV, et al. Paclitaxel-induced neuropathy: potential as-
sociation of MAPT and GSK3B genotypes. BMC Cancer 2014
Dec 22;14:993. http://dx.doi.org/10.1186/1471-2407-14-993.
[17] Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R,
Becouarn Y, et al. FOLFIRINOX versus gemcitabine for meta-
static pancreatic cancer. N Engl J Med 2011 May 12;364(19):
1817e25.
[18] Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ.
Chemotherapy regimens for advanced pancreatic cancer: a sys-
tematic review and network meta-analysis. BMC Cancer 2014 Jun
27;14:471.
[19] Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H,
Gibson AA, Du G, et al. Oxaliplatin-induced neurotoxicity is
dependent on the organic cation transporter OCT2. Proc Natl
Acad Sci U S A 2013 Jul 2;110(27):11199e204.
[20] Eloxatin (oxaliplatin) [package insert]. Bridgewater, NJ: Sanofi-
aventis U.S. LLC; 2014.
[21] de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A,
Cassidy J, et al. Leucovorin and fluorouracil with or without
oxaliplatin as first-line treatment in advanced colorectal cancer. J
Clin Oncol 2000 Aug;18(16):2938e47.
[22] Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML,
Kiernan MC. Long-term neuropathy after oxaliplatin treatment:
challenging the dictum of reversibility. Oncologist 2011;16(5):
708e16.
[23] Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC,
Goldstein D. Impact of oxaliplatin-induced neuropathy: a patient
perspective. Support Care Cancer 2012 Nov;20(11):2959e67.
